News | News By Subject | News by Disease News By Date | Search News

Muscular Dystrophy News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Humana (HUM) to Cover Sarepta (SRPT)'s Controversial DMD Drug But There's a Catch     10/27/2016
Sarepta (SRPT) Gets No Love From the FDA's New Drugs Director     10/21/2016
PTC Therapeutics (PTCT) Tanks After the FDA Denies DMD Drug Translarna Again     10/17/2016
Watch Out, Ionis Pharma (IONS): Could This Little Biotech’s Experimental SMA Treatment Be a Threat?     10/17/2016
Sarepta (SRPT) Goes for a New DMD Combo With New $562 Million+ Deal With Summit Therapeutics     10/4/2016
Saga Continues for Sarepta (SRPT) as FDA Head Calls for Retraction of 'Misleading' 2013 Study     9/23/2016
Victory at Last! Sarepta (SRPT) Stock Doubles as the FDA Finally Approves DMD Drug     9/20/2016
Turn the Page: Sarepta (SRPT) Stock Pops on Rumors DMD Drug Naysayer Leaves the FDA     9/15/2016
Sarepta (SRPT)’s Duchene Muscular Dystrophy Drug: Evaluating the Placebo Effect     8/19/2016
Sarepta (SRPT) Stock Surges After Government Website Indicates Firm is Recruiting for Phase III Study     8/5/2016
FDA Hits DMD Drugmaker Santhera (SANN.SW) With Lengthy Delay     7/14/2016
This Year’s Top 10 Disappointing Clinical Trials—So Far!     7/6/2016
Sarepta (SRPT)'s Study Period Extension May Help Gain DMD Drug Approval in the Long Run     6/24/2016
If Spurned By Medivation (MDVN), Sanofi (SNY) May Turn to BioMarin (BMRN) for a Little Love     6/17/2016
Sarepta (SRPT) Surges Yet Again, as the FDA Requests More Data About Duchenne’s Drug     6/7/2016

News from Around the Web
PTC Therapeutics (PTCT) Wants a Slice of Sarepta (SRPT)'s DMD Pie, Says Rejected Drug May Help Some Patients     10/7/2016
After Sarepta (SRPT)'s Win, BioMarin (BMRN) Wants a Piece of the Action Too     9/23/2016
Approving A Muscular Dystrophy Drug Exposes A Civil War At The FDA     9/20/2016
Approving Sarepta (SRPT)'s DMD Drug Could Force FDA To Get Creative     5/26/2016
Robotic Arm For Duchenne Patients Developed, University of Twente Reveals     1/25/2016
"Ringo The Dog" Helps Find Potential New Therapy For Muscular Dystrophy     11/18/2015
Scientists Make Diseased Cells Synthesize Their Own Drug, The Scripps Research Institute Reveals     9/4/2014
Viagra And Cialis Could Help Treat Duchenne Muscular Dystrophy, Cedars--Sinai Heart Institute Study     5/8/2014
What The Delay Of A Promising Muscular Dystrophy Drug Means For Patients, Investors And All Of Biotech     11/13/2013
Double Gene Flaws Lead to Rare Muscular Dystrophy, University of Rochester and Fred Hutchinson Cancer Research Center Study     11/14/2012
New Muscular Dystrophy Treatment Offers Hope, North Shore-Long Island Jewish Research Institute Study     3/24/2011
Human Protein Improves Muscle Function of Muscular Dystrophy in Mice, Brown University Study     12/28/2010
Viagra May Help Heart Effects of Muscular Dystrophy, University of Washington and University of North Carolina Study Finds     10/19/2010
Tarantula Venom Used in Research for Muscular Dystrophy, University at Buffalo Study     10/5/2010
Add to Human Genome's Greatest Hits: DNA Culprits That Cause FSH Muscular Dystrophy Found, Leiden University Medical Center and University of Rochester Study     8/23/2010

Press Releases
Catabasis (CATB) Provides Edasalonexent And Rare Disease Pipeline Updates At Investor Day     11/17/2016
PTC Therapeutics (PTCT) Rockets as DMD Drug Wins Extended European Approval     11/11/2016
Capricor Therapeutics, Inc. Announces Plans To Expand Clinical Development Program In Duchenne Muscular Dystrophy To Evaluate Peripheral And Respiratory Muscle Function     11/11/2016
cTAP Announces Two Research Publications Categorizing And Predicting Disease Progression In Duchenne Muscular Dystrophy     10/31/2016
CureDuchenne Release: Non-Profits, Pharmaceutical Companies And Noted Clinicians Collaborate To Launch The Collaborative Trajectory Analysis Project (Ctap); Advancing Clinical Trial Design For Duchenne Muscular Dystrophy     10/25/2016
Catabasis (CATB) Presents Positive Data From Part A Of The MoveDMD Trial Of Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy For DMD, At The World Muscle Society Congress     10/6/2016
Catabasis (CATB) Completes Target Enrollment For Part B Of The MoveDMD Trial, A Phase II Trial Of Edasalonexent (CAT-1004) For The Potential Treatment Of Duchenne Muscular Dystrophy     10/4/2016
Sarepta (SRPT) Announces First Patient Dosed In Phase III Clinical Trial Of SRP-4045 And SRP-4053 For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 45 Or 53 Skipping     9/29/2016
Catabasis (CATB) And Sarepta (SRPT) Announce A Joint Research Collaboration In Duchenne Muscular Dystrophy     9/29/2016
With Its Eyes on the DMD Drug Prize, Sarepta (SRPT) to Raise $225 Million in Stock Sale     9/22/2016
Sarepta (SRPT) Announces FDA Accelerated Approval Of EXONDYS 51 (Eteplirsen) Injection, An Exon Skipping Therapy To Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable To Skipping Exon 51     9/19/2016
FDA Allows Phrixus Pharmaceuticals' IND For Carmeseal-MD (P-188 NF) In Duchenne Muscular Dystrophy (DMD)     9/7/2016
FDA Accepts Marathon Pharma’ New Drug Applications For Deflazacort For The Treatment Of Duchenne Muscular Dystrophy And Grants Priority Review     8/10/2016
Acceleron Pharma Announces ACE-083 Phase 1 Results At The 14th International Congress On Neuromuscular Diseases     7/8/2016
Catabasis (CATB) Announces The Initiation Of An Open-Label Extension For The Movedmd Trial Studying Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy     7/7/2016

//-->